Free Trial

ESSA Pharma (EPIX) Competitors

ESSA Pharma logo
$1.88 +0.01 (+0.27%)
As of 07/25/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

EPIX vs. ALT, AMRN, PVLA, RCKT, IVA, ALDX, NGNE, CAPR, RNAC, and OLMA

Should you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include Altimmune (ALT), Amarin (AMRN), Palvella Therapeutics (PVLA), Rocket Pharmaceuticals (RCKT), Inventiva (IVA), Aldeyra Therapeutics (ALDX), Neurogene (NGNE), Capricor Therapeutics (CAPR), Cartesian Therapeutics (RNAC), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry.

ESSA Pharma vs. Its Competitors

Altimmune (NASDAQ:ALT) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

78.1% of Altimmune shares are held by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are held by institutional investors. 4.1% of Altimmune shares are held by company insiders. Comparatively, 15.5% of ESSA Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Altimmune has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.

ESSA Pharma has a net margin of 0.00% compared to Altimmune's net margin of -451,200.00%. ESSA Pharma's return on equity of -23.48% beat Altimmune's return on equity.

Company Net Margins Return on Equity Return on Assets
Altimmune-451,200.00% -65.44% -58.43%
ESSA Pharma N/A -23.48%-22.86%

ESSA Pharma has lower revenue, but higher earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Altimmune$20K16,545.83-$95.06M-$1.26-3.24
ESSA PharmaN/AN/A-$28.54M-$0.63-2.98

Altimmune currently has a consensus price target of $18.20, indicating a potential upside of 346.08%. ESSA Pharma has a consensus price target of $2.00, indicating a potential upside of 6.38%. Given Altimmune's stronger consensus rating and higher probable upside, equities analysts plainly believe Altimmune is more favorable than ESSA Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Altimmune
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75
ESSA Pharma
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Altimmune had 6 more articles in the media than ESSA Pharma. MarketBeat recorded 8 mentions for Altimmune and 2 mentions for ESSA Pharma. ESSA Pharma's average media sentiment score of 0.93 beat Altimmune's score of 0.33 indicating that ESSA Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Altimmune
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
ESSA Pharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

ESSA Pharma beats Altimmune on 9 of the 16 factors compared between the two stocks.

Get ESSA Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EPIX vs. The Competition

MetricESSA PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$83.01M$2.49B$5.69B$9.50B
Dividend YieldN/A1.65%4.58%4.01%
P/E Ratio-2.989.0528.1020.05
Price / SalesN/A612.51432.4490.07
Price / CashN/A165.2136.2258.56
Price / Book0.675.168.665.87
Net Income-$28.54M$30.99M$3.25B$258.55M
7 Day PerformanceN/A7.74%4.23%3.74%
1 Month Performance8.05%16.27%10.52%11.75%
1 Year Performance-64.79%-1.88%34.41%18.03%

ESSA Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EPIX
ESSA Pharma
0.939 of 5 stars
$1.88
+0.5%
$2.00
+6.4%
-65.3%$83.01MN/A-2.9850
ALT
Altimmune
2.1026 of 5 stars
$4.05
-0.7%
$18.20
+349.4%
-39.0%$330.92M$20K0.0050
AMRN
Amarin
0.2434 of 5 stars
$15.55
-1.7%
$12.00
-22.8%
-2.7%$327.58M$228.61M-4.27360Positive News
Upcoming Earnings
PVLA
Palvella Therapeutics
1.4301 of 5 stars
$31.00
+5.0%
$47.50
+53.2%
N/A$326.25M$42.81M0.00N/A
RCKT
Rocket Pharmaceuticals
4.8425 of 5 stars
$3.13
+3.0%
$18.60
+494.2%
-87.9%$324.63MN/A-1.19240Trending News
Analyst Forecast
Analyst Revision
Gap Down
IVA
Inventiva
3.3908 of 5 stars
$3.21
-5.3%
$10.40
+224.0%
+37.5%$324.29M$9.95M0.00100Positive News
Gap Down
ALDX
Aldeyra Therapeutics
2.5136 of 5 stars
$5.39
flat
$9.50
+76.3%
+26.4%$322.84MN/A-5.5610Upcoming Earnings
Gap Up
NGNE
Neurogene
3.5663 of 5 stars
$21.66
-3.0%
$46.17
+113.1%
-46.8%$318.61M$930K0.0090
CAPR
Capricor Therapeutics
2.7488 of 5 stars
$6.27
-8.9%
$22.56
+259.7%
+59.4%$314.26M$22.27M-4.42101Trending News
Gap Up
RNAC
Cartesian Therapeutics
2.3061 of 5 stars
$12.05
+1.8%
$40.00
+232.0%
-19.6%$307.30M$38.91M0.0064News Coverage
Positive News
Gap Up
OLMA
Olema Pharmaceuticals
2.4168 of 5 stars
$4.59
+4.1%
$24.50
+433.8%
-67.9%$301.74MN/A0.0070

Related Companies and Tools


This page (NASDAQ:EPIX) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners